Source comparison
Best Peptides for Spinal Cord Injury: Research-Grade Comparison
This table compares the three most-studied peptides in spinal cord injury research based on mechanism, evidence quality, and practical considerations for research applications. Thymosin Beta-4 (Tβ4) Modulates inflammation, reduces microglial activation, suppor
This comparison does not assign a generated winner or score.
- This table compares the three most-studied peptides in spinal cord injury research based on mechanism, evidence quality, and practical considerations for research applications.
- Thymosin Beta-4 (Tβ4)
- Modulates inflammation, reduces microglial activation, supports cell migration to injury sites
- 14+ rodent SCI studies; systematic review shows 2.8–4.1 point BBB score improvement vs controls
- Intraperitoneal (animal models), subcutaneous (theoretical human use)
- 6–42 mg/kg in rodents; human equivalent dose ~0.5–3.5 mg/kg (not clinically validated)
- Strongest evidence for early-phase neuroprotection; effective within 6–12 hour window; limited human data
- BPC-157
- Promotes angiogenesis via VEGF upregulation, stabilizes nitric oxide pathways, supports blood-spinal cord barrier integrity
- Multiple rodent studies; heterogeneous effect sizes depending on injury severity and location
- Intraperitoneal, intramuscular
- 10 μg/kg to 10 mg/kg in rodents; no established dose-response curve
- Consistent angiogenic effects; functional outcomes variable; minimal human safety data for CNS applications
- Cerebrolysin
- Provides exogenous neurotrophic factors (BDNF, NGF, CNTF); supports neuronal survival and axonal sprouting
- Phase II human SCI trial (n=46); extensive stroke/TBI literature; Cochrane review shows modest effect
- Intravenous infusion
- 50 mL/day IV for 21 days (human dosing from stroke trials); animal dosing ~2.5–5 mL/kg
- Only peptide with published human SCI trial data; modest functional improvements; requires clinical administration infrastructure